Law 2011-2012 of December 29, 2011, relating to the reinforcement of the safety of drugs and medicinal products, has modified the French public health code.
Law 2011-2012 of December 29, 2011, relating to the reinforcement of the safety of drugs and medicinal products, has modified the Code de la Santé Publique (CSP, the French public health code). It includes two articles that affect the extent of the exclusive rights of intellectual property owners.
The law brings in a new article to the CSP, stating that: “The holder of an IP right protecting the appearance and texture of oral dosage forms of a specialty of reference within the meaning of Article L. 5121-1 may not prohibit oral dosage forms of a generic specialty which may be substituted for that specialty in pursuance of Article L. 5125-23 from presenting an identical or similar appearance and texture.”
It means that now, in France, generic companies will not only be able to refer to the original trademark in their own products, rather than to the international non-proprietary name (INN), but they will even been allowed to reproduce the shape of the branded medicine itself, even in cases when there is no medical need for it.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
Generic drugs, CSP